LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.13 4.63

Buy Sell

Overview

Share price change

24h

Current

Min

1.12

Max

1.1400000000000001

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+380.91% upside

Market Stats
By TradingEconomics
Market Cap	-1.1M 125M
Previous open	-3.5
Previous close	1.13

News Sentiment

By Acuity

52%

48%

306 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 lis 2025, 15:29 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28 lis 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 lis 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28 lis 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28 lis 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28 lis 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28 lis 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28 lis 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28 lis 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28 lis 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28 lis 2025, 16:50 UTC

Acquisitions, Mergers, Takeovers

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28 lis 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28 lis 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28 lis 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28 lis 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28 lis 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28 lis 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28 lis 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28 lis 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28 lis 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28 lis 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 lis 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28 lis 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28 lis 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28 lis 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 lis 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28 lis 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28 lis 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28 lis 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28 lis 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

380.91% upside

12 Months Forecast

Average 5.29 USD 380.91%

High 8 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

306 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.